BioCatalyst

Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose — catalyst calendar

1 verified catalyst event(s) referencing Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose, each linked to its official source. Verified as of 2026-10-17.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-11 (month)
in 15d
ESTIMATED
 READOUT
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Der
Phase 3 · Atopic Dermatitis
 ABBV AbbVie Inc. Upadacitinib 15mg Dose, Dupilumab 300mg ClinicalTrials.gov ↗
✓ Source-checked 2026-10-17
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.